Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BiomX Inc. PHGE
$0.29
+$0.04 (13.40%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8959086.00000000
-
week52high
1.17
-
week52low
0.13
-
Revenue
-134000
-
P/E TTM
0
-
Beta
1.31009700
-
EPS
-0.94000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 24 мая 2022 г. |
| Ladenburg Thalmann | Buy | Buy | 12 мая 2022 г. |
| Chardan Capital | Buy | Buy | 16 ноя 2021 г. |
| Chardan Capital | Buy | Buy | 19 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 18 окт 2021 г. |
| Chardan Capital | Buy | Buy | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ugwumba Chidozie | D | 2997025 | 1501 | 04 ноя 2022 г. |
| Ugwumba Chidozie | D | 2998526 | 2000 | 03 ноя 2022 г. |
| Ugwumba Chidozie | D | 3000526 | 2416 | 02 ноя 2022 г. |
| Ugwumba Chidozie | D | 3002942 | 1300 | 01 ноя 2022 г. |
| Ugwumba Chidozie | D | 3004242 | 3300 | 31 окт 2022 г. |
| Ugwumba Chidozie | D | 3007542 | 1526 | 28 окт 2022 г. |
| Ugwumba Chidozie | D | 3009068 | 1505 | 27 окт 2022 г. |
| Ugwumba Chidozie | D | 3010573 | 12500 | 26 окт 2022 г. |
| Ugwumba Chidozie | D | 3023073 | 3072 | 25 окт 2022 г. |
| Ugwumba Chidozie | D | 3026145 | 5900 | 24 окт 2022 г. |
Новостная лента
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
GlobeNewsWire
29 ноя 2022 г. в 09:10
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.
BiomX, Inc. (PHGE) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 06:41
BiomX, Inc. (NYSE:PHGE ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Mike Higgins - Ladenburg Thalmann Richard Miller - Cantor Fitzgerald Operator Good morning, and welcome to the BiomX Third Quarter 2022 Financial Results and Corporate Update Conference Call.
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
Business Wire
11 сент 2022 г. в 07:22
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C Wainwright Global Investment Conference – September 12-14, 2022 Date & Time: Mond
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
11 авг 2022 г. в 17:12
BiomX Inc. (NYSE:PHGE ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Marina Wolfson - Chief Financial Officer Jonathan Solomon - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kristen Kluska – Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Keay Nakae - Chardan Operator Good morning.
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
Business Wire
07 авг 2022 г. в 03:17
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call